Table 1. Clinical trials of mesenchymal stromal cells in ARDS.

Clinicaltrials.gov	Country	Cell type	Placebo	Dose	Delivery	Follow-up	Patients
Published clinical trials
NCT01902082	China	AD-MSC	Saline	106/kg	IV	7 days	12 (6/6)
NCT01775774	USA	BM-MSC	No	1, 5, 10×106/kg	IV	12 months	9 (3/3/3)
NCT02097641	USA	BM-MSC	Plasmalyte	107/kg	IV	12 months	60 (40/20)
Ongoing clinical trials
NCT02444455	China	UC-MSC	No	5×105/kg/day (3 days)	IV	14 days	20
NCT02112500	Korea	BM-MSC	No	Not reported	IV	28 days	10
NCT02215811	Sweden	BM-MSC	No	Not reported	Not reported	12 months	10
NCT02095444	China	MB-MSC	No	107/kg/week (2 weeks)	IV	14 days	20
NCT02611609	UK	Multistem®	Saline	Not reported	Not reported	12 months	36 (12/12/12)
NCT03042143	UK	UC-CD362 MSC	Plasmalyte	1, 2, 4×108 cells	IV	14 days	75
NCT02804945	USA	BM-MSC	Plasmalyte	3×106 cell/kg	IV	60 days	50
NCT03608592	China	UC-MSC	Saline	60×106 cells	IV	28 days	12
NCT03818854	USA	BM-MSC	Cell reconstitution media	107 cells/kg	IV	60 days	120

Mesenchymal stromal cell (MSC) clinical trials in ARDS patients. ARDS, acute respiratory distress syndrome; AD, adipose-derived; BM, bone marrow-derived; UC, umbilical cord-derived; MB, menstrual blood-derived; IV, intravenous.